Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 4/20 | 0.48 |
| ▸ | LHCGR | P22888 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439863 | 1.00 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1KDM4E | |
| SCHEMBL4018143 | 1.00 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL5239130 | 0.99 | HHAT (0.47) | HHATLHCGRNPSR1MAPK1KDM4E | |
| Bromide SCHEMBL4019730 | 0.99 | HHAT (0.47) | HHATLHCGRNPSR1MAPK1KDM4E | |
| SCHEMBL24419940 | 0.86 | HHAT (0.52) | HHATLHCGR | |
| SCHEMBL2307868 | 0.86 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1DRD1 | |
| SCHEMBL4738266 | 0.86 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1DRD1 | |
| SCHEMBL2916838 | 0.83 | HDAC8 (0.42) | NPSR1KDM4EDRD1 | |
| Sulfuric Acid SCHEMBL2306919 | 0.82 | HHAT (0.45) | HHATLHCGRDRD1 | |
| SCHEMBL5769463 | 0.79 | HHAT (0.38) | HHATLHCGRNPSR1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011506950-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20110041589-A1 | NEW HPCL METHOD | GENERICS [UK] LIMITED (GB) | 2011-02-24 | — | — | US | claimed |
| EP-2220484-A2 | HPLC METHOD FOR ANALYSING CLOPIDOGREL | Generics [UK] Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| WO-2009077784-A2 | HPCL METHOD FOR ANALYSING CLOPIDOGREL | GENERICS [UK] LIMITED (GB) | 2009-06-25 | — | — | WO | claimed |
| US-20180125782-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | HUANG JINGJUN (US) | 2018-05-10 | — | — | US | disclosed |
| US-9884016-B2 | Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery | ASCENDIA PHARMACEUTICALS LLC | 2018-02-06 | — | — | US | disclosed |
| US-20170014343-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | ASCENDIA PHARMACEUTICALS LLC | 2017-01-19 | — | — | US | disclosed |
| US-9480680-B2 | Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery | ASCENDIA PHARMACEUTICALS LLC | 2016-11-01 | — | — | US | disclosed |
| EP-2953613-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | Huang, Jingjun (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014124132-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | HUANG JINGJUN (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140227360-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | ASCENDIA PHARMACEUTICALS LLC | 2014-08-14 | — | — | US | disclosed |
| WO-2013133620-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CLOPIDOGREL AND ASPIRIN AND PROCESS FOR PREPARING THE SAME | YUHAN CORPORATION (KR) | 2013-09-12 | — | — | WO | disclosed |
| EP-2121704-A2 | POLYMORPHIC FORMS OF CLOPIDOGREL HYDROBROMIDE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008108742-A2 | POLYMORPHIC FORMS OF CLOPIDOGREL HYDROBROMIDE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2008-09-12 | — | — | WO | disclosed |
| US-20070225320-A1 | PROCESS FOR PREPARING CLOPIDOGREL | DR. REDDY'S LABORATORIES, INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1750701-A1 | AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE | IVAX Pharmaceuticals s.r.o. (CZ) | 2007-02-14 | — | — | EP | disclosed |
| EP-1750701-A1 | AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE | IVAX Pharmaceuticals s.r.o. (CZ) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006023676-A1 | CLOPIDOGREL NAPSYLATE SALT | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005117866-A1 | AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005117866-A1 | AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227360-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | CEL, SELP, P2RY12 | HHAT 1687/4885LHCGR 3886/4885NPSR1 569/4885 |
| US-20180125782-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | P2RY12, P2RY11, SELP | HHAT 1317/4885LHCGR 3774/4885NPSR1 310/4885 |
| US-20070225320-A1 | PROCESS FOR PREPARING CLOPIDOGREL | PFKP, SELP, P2RY13 | HHAT 3793/4885LHCGR 3799/4885NPSR1 626/4885 |
| US-20170014343-A1 | STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY | P2RY12, P2RY11, SELP | HHAT 1317/4885LHCGR 3774/4885NPSR1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.